Novo Nordisk's concizumab trials can resume after safety trial halt

Novo Nordisk
(Novo Nordisk)

Danish drugmaker Novo Nordisk is opening up its bleeding disorder trials five months after they were stopped.  

Back in March, Novo was forced to halted one midstage and two late-stage tests of its bleeding disease drug concizumab after seeing blood clots in some patients.

Concizumab is a key part of Novo’s expanding hemophilia pipeline, but the safety concerns saw it pause specifically two trials in its phase 3 program (known as explorer7 and 8) and one study in the phase 2 program (explorer5).

Featured Whitepaper

Accelerate Clinical Operations Across Sponsors, CROs, and Partners

The most advanced life sciences organizations know that digital innovation and multi-platform integrations are essential for enabling product development. New platforms are providing the life sciences industry with an opportunity to improve the efficiency of clinical trials and reduce costs while remaining compliant and reducing risk.

These were testing concizumab as a prophylactic treatment in both hemophilia A and B patients regardless of inhibitor status.

But now Novo says that its two phase 3 programs, namely explorer 6, 7 and 8 are being resumed.   

The company said in a statement. “Novo Nordisk has together with relevant authorities identified a new path forward for concizumab. New safety measures and guidelines, based on analysis of all available data, have been agreed with the FDA and the clinical hold has been lifted.”

The drug works as an antibody designed to target a natural anticoagulant protein called tissue factor pathway inhibitor (TFPI). It is hoping to rival Roche’s Hemlibra, though the future looks like it will be made up of one and done gene therapies (though both safety and efficacy need to be proved here).

Mads Krogsgaard Thomsen, EVP and chief scientific officer of Novo Nordisk, said: “I am pleased that we are able to safely restart the explorer trials. This emphasizes Novo Nordisk’s long-term dedication to the haemophilia community and our commitment to develop new subcutaneous prophylaxis options for all haemophilia patients.”

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

The trial squeezed under the bar for statistical significance by improving on the median progression-free survival of Zytiga by two months.